Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.
- Parkinson's disease
- Positron emission tomography